Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF

Bone Marrow Transplantation

Volumn 17, Issue 2, 1996, Pages 179-183

  Rosenfeld, C S ^a,h   Bolwell, B ^b   LeFever, A ^c   Taylor, R ^c   List, A ^d   Fay, J ^a   Collins, R ^a   Andrews, F ^e   Pallansch, P ^e   Schuster, M W ^f   Resta, D ^g   Levitt, D ^g   Nemunaitis, J ^a  

^a TEXAS ONCOLOGY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c ST LUKE S MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e W Pennsylvania Cancer Institute   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g Sandoz Pharma Ltd   (Switzerland)

^h Stem Cell Transplant and Res Prog   (United States)

Author keywords

Autologous bone marrow transplantation; Breast neoplasms; Granulocyte macrophage colony stimulating factor; Interleukin 3; Lymphoma; Transplantation

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CELL MIGRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; FEMALE; FEVER; GRAFT PATENCY; HEADACHE; HODGKIN DISEASE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; LEUKEMIA; LYMPHOMA; MALE; MONONUCLEAR CELL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

ADULT; BONE MARROW; BREAST NEOPLASMS; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ETOPOSIDE; FEMALE; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; INTERLEUKIN-3; LEUKAPHERESIS; LEUKEMIA; LEUKOCYTE COUNT; LYMPHOMA; MALE; MIDDLE AGED; NEUTROPHILS; PROSPECTIVE STUDIES; THIOTEPA; WHOLE-BODY IRRADIATION;

EID: 9044219841     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Rosenfeld CS, Nemunaitis J. The role of granulocyte-macrophage colony-stimulating factor-stimulated progenitor cells in oncology. Semin Hematol 1992; 29: 19-26.
2. Rosenfeld CS, Gremba C, Shadduck RK et al. Engraftment with peripheral blood stem cells using non-controlled rate cryopreservation: comparison with autologous marrow transplantation. Exp Hematol 1994; 22: 290-294.
3. To LB, Roberts MM, Haylock DN er al. Comparison of hematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
4. Bensinger W, Singer J, Appelbaum F et al. Autologous transplantation with peripheral blood mononuclear cells collected after administration of recombinant granulocyte colony stimulating factor. Blood 1993; 81: 3158-3163.
5. Sheridan WP, Begley CG, Juttner CA et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640-644.
6. Pettengell R, Morgenstern GR, Woll PJ et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-3777.
7. Nademanee A, Schmidt GM, Sniecinski IR et al. G-CSF primed peripheral blood stem cell autographs in patients with advanced lymphoid malignancies. Proc ASCO 1992; 11: 317 (abstr 1075).
8. Chao NJ, Schriber JF, Grimes K et al. Granulocyte colonystimulating factor 'mobilized' peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031-2035.
9. de Vries EGE, van Gameren MM, Willemse PHB. Recombinant human interleukin-3 in clinical oncology. Stem Cells 1993; 11: 72-80.
10. Emerson SG, Yang Y-C, Clark SC, Long MW. Human recombinant granulocyte-macrophage colony-stimulating factor and interleukin-3 have overlapping but distinct hematopoietic activities. J Clin Invest 1988; 82: 1282-1287.
11. Ottmann OG, Ganser A, Seipelt G et al. Effects of recombinant human interleukin-3 on human hematopoietic progenitor and precursor cells in vivo. Blood 1990; 76: 1494-1502.
12. D'Hondt V, Weynants P, Humblet Y et al. Dose-dependent interleukin-3 stimulating of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: a placebo-controlled randomized Phase 1b study. J Clin Oncol 1993; 11: 2063-2071.
13. Ganser A, Lindemann A, Ottmann OG et al. Sequential in vivo treatment with two recombinant human hematopoietic growth factors (interleukin-3 and granulocyte-macrophage colony-stimulating factor) as a new therapeutic modality to stimulate hematopoiesis: results of a phase I study. Blood 1992; 79: 2583-2591.
14. Donahue RE, Seehra J, Metzger M et al. Human IL-3 and GM-CSF act synergistically in stimulating hematopoiesis in primates Science 1988; 24: 1820-1823.
15. Geissler K, Valent P, Mayer P et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates - synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood 1990; 75: 2305-2310.
16. Rosenfeld CS, Cullis H, Nemunaitis J. Peripheral blood stem cell collection using the small volume collection chamber in the Fenwal CS-3000 Plus blood cell separator. Bone Marrow Transplant 1994; 13: 131.
17. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 1992; 10: 102-110.
18. Jagannath S, Dicke KA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163-168.
19. Gonzales-Chambers R, Przepiorka D, Shadduck RK et al. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow for acute lymphoblastic leukemia Med Pediatr Oncol 1991; 19: 160-164.
20. Vaughan WP, Dennison JD, Reed EC et al. Improved results of allogeneic bone marrow transplantation for advanced hematologic malignancy using busulfan, cyclophosphamide and etoposide as cytoreductive and immunosuppressive therapy. Bone Marrow Transplant 1991; 8: 489-495.
21. Brown RA, Wolff S, Fay J et al. High-dose etoposide, cyclophosphamide, total body irradiation (VP/CY/TBI) and allogeneic bone marrow transplant (BMT) for patients with resistant acute myeloid leukemia (AML): a phase I-II trial by the North American Marrow Transplant Group. Blood 1993; 82: 10 (suppl. 1) 166a.
22. Nemunaitis J, Rabinowe SN, Singer JW et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. New Engl J Med 1991; 324: 1773-1778.
23. Ganser A, Lindemann A, Seipelt G et al. Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 1990; 76: 666-676.
24. Lindemann A, Ganser A, Herrmann F et al. Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 1988; 9: 2120-2127.
25. Paquette RL, Zhou JY, Yang YC et al. Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood 1988; 71: 1596-1600.
26. Ulich TR, del Castillo J, McNiece IK et al. Acute and subacute hematologic effects of multi-colony stimulating factor in combination with granulocyte colony-stimulating factor in vivo. Blood 1990; 75: 48-53.